- Home
- RIGL vs YDES Comparison
RIGL vs YDES Comparison
Compare RIGL & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | YDES |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 543.0M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | YDES |
|---|---|---|
| Price | $29.20 | $4.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 386.9K | 4.9K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | $66.97 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.14 | $4.37 |
| 52 Week High | $52.24 | $25.00 |
Technical Indicators
Market Signals| Indicator | RIGL | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 36.94 |
| Support Level | $28.08 | $4.73 |
| Resistance Level | $32.17 | $5.36 |
| Average True Range (ATR) | 1.99 | 0.23 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 48.15 | 38.02 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.